Seong-Jun Kang, Ph.D.

Experimental and computational biomedical scientist: human skin biology, single-cell and spatial profiling, machine-learning phenotyping
Postdoctoral Associate applicant · MIT Jameel Clinic · Yilmaz Lab (Koch Institute) and Barzilay Group (CSAIL)
101 Canal Street
Boston, MA 02114
(551) 239-0341
sjkang89@gmail.com
Available August 2026
Research profileI run single-cell and spatial measurements on human tissue and build the models that read them. Five of my papers are on human skin, including atopic dermatitis, psoriasis, mycosis-fungoides-like inflammatory disease, and melanoma arising from a congenital melanocytic nevus, where I ran the GeoMx spatial workflow end to end and stained the S100B melanocyte marker by hand. In one immune-disease project I went from phenotyping 251,055 memory CD4⁺ T cells to a target and then to a selective inhibitor that lowered the pathogenic fraction. My current work is deep-learning multimodal integration of imaging, transcriptomic and clinical data.

Position-Relevant Expertise

  • Human skin and pigmented tissue. Five studies on atopic dermatitis, psoriasis, mycosis-fungoides-like inflammatory disease, and melanoma arising from congenital melanocytic nevus. Skin dissociation, IHC/IF on frozen and FFPE tissue, spatial profiling, and single-cell analysis.
  • Phenotyping and target discovery. Disease-associated cell-state programs defined by consensus NMF from high-dimensional single-cell data, isoform-resolved analysis written from scratch, replication in an independent atlas, and then a causal and pharmacological test of the state.
  • Spatial and single-cell measurement. GeoMx DSP end to end, Visium, MACSima cyclic multiplexed immunofluorescence, scRNA-seq, scTCR-seq, snATAC-seq, quantitative imaging, and multimodal integration across those layers.
  • Machine learning. Deep-learning integration of imaging, transcriptomic and clinical data; a vision-language model adapted by LoRA so a pathology tile returns a structured reading, held out at the case level; PyTorch, scikit-learn, gradient boosting, calibrated classification, and evaluation held out at donor or case level.
  • Study design that a model can learn from. Donor pooling with SNP demultiplexing so donor and run stay separable, multi-site QC across more than 700 donors, automated library preparation on the 10x Chromium Connect, and plate, batch, donor and imaging round kept out of the label.
  • Grant writing. About $1.3 million across five industry proposals, lead writer on four, always under the institutional PI and not as PI. K99/R00 and LSRF are open to me, and I would apply within the first two years.

Education

Degrees
Ph.D.2014–2023
Seoul National University, Seoul, Republic of Korea
Department of Biomedical Sciences
Thesis: Exploration of the Role of Regulatory T cells in Various Pathogenic Contexts
Advisor: Chung-Gyu Park, M.D., Ph.D.
M.S.2012–2014
Seoul National University, Seoul, Republic of Korea
Department of Biomedical Sciences
Thesis: Enhanced LPS-Induced Monocyte Activation by Recombinant Human Soluble CD14
Advisor: Chung-Gyu Park, M.D., Ph.D.
B.S.2008–2012
Sungkyunkwan University, Suwon, Republic of Korea
Department of Genetic Engineering

Research & Professional Experience

Researcher
(postdoctoral)2025–present
Yonsei University Wonju College of Medicine · Dept. of Physiology / Organelle Medicine Research Center, Wonju, Republic of Korea
Deep-learning multimodal-integration models fusing imaging, transcriptomic, and clinical data into single predictive models.
Associate Director2023–2025
PB Immune Therapeutics Inc. · Dept. of Basic Research, Seoul, Republic of Korea
Led a humanized anti-CD40 antibody program: candidate ranking by surface plasmon resonance (Biacore) and ELISA, receptor-blocking confirmation, human and non-human-primate cross-reactivity, in vivo efficacy in primates, and the regulatory documentation. Placed and oversaw CRO and core-facility work, from study design and assay conditions through data delivery and go/no-go calls. Built the in-house single-cell and spatial analysis pipeline. Ran cynomolgus and marmoset EAE studies for multiple sclerosis programs.
Manager2021–2023
PB Immune Therapeutics Inc. · Dept. of Basic Research, Seoul, Republic of Korea
Wrote the two KDDF proposals that funded the anti-CD40 program and ran the lead-selection work under them.
Research Student2020–2023
SCAID, Single Cell Atlas of Immune Diseases, Genomic Medicine Institute, Seoul National University, Seoul, Republic of Korea
Contributed the founding proposal; executed within the funded program (700+ donors × 8 organs): milestone tracking, multi-site QC, multi-PI coordination.
Researcher2019–2021
Xenotransplantation Research Center, Seoul National University, Seoul, Republic of Korea
Rhesus macaque tissue processing and longitudinal immune monitoring across transplantation studies.
Teaching Assistant2014–2016
Seoul National University College of Medicine · Dept. of Microbiology and Immunology, Seoul, Republic of Korea

Selected Research Outputs

  1. Youngkyoung Lim*, Seong-Jun Kang*, Beom Keun Cho, Hyun Je Kim, … Chong Hyun Won, Chung-Gyu Park. "Intra-tumoral heterogeneity and immune escape of melanoma arising from congenital melanocytic nevus revealed by spatial gene expression profiling." JEADV 2022. Download PDFPigmented tissue measured in situ. Ran GeoMx DSP end to end, including the S100B melanocyte-marker immunofluorescence stained by hand, fluorescence-guided ROI selection and instrument operation. The lesion was segmented by invasion depth from 300 to 4,200 μm Breslow, 16 whole-transcriptome ROIs; HLA class I and II were lost in a graded way with depth and B2M loss was confirmed by immunohistochemistry.
  2. Woogil Song*, Seong-Jun Kang*, Taehee Stella Kim*, Seyoung Jung, Sung Hee Kim, Su Chan Park, Sung Hae Chang, Eun Young Lee, Tae-Gyun Kim, Hyun Je Kim, Jeong Seok Lee. "Conserved PDE4D short-isoform bias defines pathogenic Th1.17 state across human inflammatory diseases." Nature Immunology 2026. in revisionPhenotype, target, and drug in one project. Custom UMI-aware, BAM-level code resolved PDE4D short- and long-isoform identity from 5′ reads across 251,055 cells. The pathogenic Th1.17 program replicated across 702 samples and 23 immune diseases. Short-isoform overexpression raised the IFN-γ⁺IL-17A⁺ fraction, the long isoform left it flat, and the PDE4D-selective inhibitor zatolmilast lowered it.
  3. Seong-Jun Kang*, Jeong-Ryeol Gong*, Seon-Pil Jin, Jin-Mi Oh, Hyunjin Jin, Yuji Lee, Yewon Moon, Dongjun Kim, Hyo Jeong Nam, Hyun Seung Choi, Sanha Hwang, Yun Jung Huh, Kyung Yeon Han, Jihwan Moon, Jongsuk Chung, Woong-Yang Park, Chung-Gyu Park, Hyun Je Kim, Jeong Eun Kim. "Deciphering Dysfunctional Regulatory T Cells in Atopic Dermatitis." Allergy 2025. Download PDFHuman skin immunology at single-cell resolution. Single-cell and functional dissection of skin-homing CLA⁺ regulatory T cells in atopic dermatitis, with OX40 up-regulated alongside impaired suppressive function.
  4. Jung Ho Lee*, Sung Ha Lim*, Hyungdon Kook, Seong-Jun Kang, Geon Lee, Brian Hyohyoung Lee, Hyunsung Nam, YongJun Kim, Christine Suh-Yun Joh, Soyoung Jeong, Dongryeol Shin, Hyun Je Kim, Jiyoung Ahn. "Mycosis Fungoides-like Atopic Dermatitis Represents a Th22-dominant Inflammatory Endotype." Allergy 2026.Telling a reactive state from a malignant one. Cross-dataset scVI integration with public cohorts, InferCNV genomic-identity inference and scTCR clonality across 248,881 cells, showing an oligoclonal Th22 inflammatory endotype rather than a malignancy.
  5. Brian Hyohyoung Lee*, Yoon Ji Bang*, Sung Ha Lim*, Seong-Jun Kang, Sung Hee Kim, Seunghee Kim-Schulze, Chung-Gyu Park, Hyun Je Kim, Tae-Gyun Kim. "High-dimensional profiling of regulatory T cells in psoriasis reveals an impaired skin-trafficking property." eBioMedicine 2024. Download PDFHigh-dimensional profiling of inflamed skin. Regulatory T cells in psoriasis profiled at high parameter, showing an impaired skin-trafficking phenotype.

Technical Expertise

Machine-learning
phenotyping
Current work at Yonsei is deep-learning multimodal integration, fusing imaging, transcriptomic and clinical data into single predictive models. Cell-state programs defined by consensus NMF (k = 14 → 12 reproducible programs across 251,055 cells), then a condition classifier on subset composition reported with held-out AUC and 95% confidence intervals (arthritis 0.780, healthy control 0.771, psoriasis 0.806). PyTorch, scikit-learn, XGBoost/LightGBM/CatBoost. Quantitative image analysis on IHC/IF, frozen and FFPE.
Skin and pigmented
tissue
Five human-skin papers: atopic dermatitis (Allergy 2025, co-first), psoriasis (eBioMedicine 2024), mycosis-fungoides-like AD (Allergy 2026), and two on melanoma arising from congenital melanocytic nevus (JEADV 2022 co-first, 2024). GeoMx DSP run end to end on the nevus melanoma, including S100B melanocyte-marker immunofluorescence stained by hand, depth-segmented sampling, and 16 whole-transcriptome ROIs. Skin tissue dissociation, frozen and FFPE IHC/IF.
Single-cell /
spatial / multi-omic
scRNA-seq, scTCR-seq, snRNA/snATAC; 10x 5′/3′ library generation and 10x Chromium Connect automated preparation. Seurat, Scanpy, Squidpy, Monocle3, CellChat/NicheNet; scVI/scANVI, batch integration, consensus NMF; Milo KNN-graph differential abundance, GLIPH, InferCNV. Custom UMI-aware, BAM-level isoform analysis code (Python). Spatial: GeoMx DSP run end to end, Visium, MACSima cyclic multiplexed immunofluorescence.
Vision-language
and retrieval models
Finetuning. LoRA adaptation of an open vision-language model (Gemma 4 12B, mlx-vlm) so that an amyloid pathology tile returns a structured JSON reading, with the schema enforced during decoding and the split held out at the case level. Against the same model zero-shot on 800 held-out tiles, cored-plaque F1 went from 0.12 to 0.44 and cerebral amyloid angiopathy from 0.00 to 0.69. Retrieval. A retrieval-augmented question-answering service written end to end: corpus chunking, BM25 and dense-vector retrieval fused by reciprocal rank, query expansion, and streamed answers that carry their sources. FastAPI, containerized, on Google Cloud Run; it answers questions about this CV at kangseongjun.com.
Computational
Python: scikit-learn, XGBoost/LightGBM/CatBoost, PyTorch; AUC-validated classifiers held out on independent cohorts; multimodal deep-learning integration (imaging + transcriptomic + clinical). Linux servers · R/RStudio · Git-based reproducible analysis.
Cell, tissue &
immunological assays
Primary human T-cell isolation, expansion and functional assays; monocyte and dendritic-cell differentiation; mesenchymal stem cell culture. Enzymatic tissue digestion, Percoll enrichment, cell and nucleus isolation. High-dimensional flow cytometry (panels up to 24 markers); multiplex panel design; 10-color 6-way FACS. Olink targeted plasma proteomics (immune & neurology panels).
Microscopy &
animal models
Spinning-disk confocal (Nikon CSU-W1 SORA), point-scanning confocal (Leica SP8), two-photon; IHC/IF (frozen & FFPE) with quantitative image analysis. Non-human primates across three species (rhesus, cynomolgus, marmoset), including EAE and islet-transplantation studies; mouse immune profiling.
Program & external
execution
CRO and core-facility work from study design and placement through data delivery and go/no-go calls; assay conditions specified to the vendor; regulatory documentation for a therapeutic antibody program; funder milestones and reporting; multi-site sample QC across a 700-donor collection.

Publications

18Total papers
17Peer-reviewed
1In revision
6First / co-first
Google Scholar · Full Profile, Citations & h-index ↗
Publications · First / Co-first Author
  • 2026Woogil Song*, Seong-Jun Kang*, Taehee Stella Kim*, Seyoung Jung, Sung Hee Kim, Su Chan Park, Sung Hae Chang, Eun Young Lee, Tae-Gyun Kim, Hyun Je Kim, Jeong Seok Lee. "Conserved PDE4D short-isoform bias defines pathogenic Th1.17 state across human inflammatory diseases." Nature Immunology. in revision
  • 2025Seong-Jun Kang*, Yong-Hee Kim*, Thuy Nguyen-Phuong*, Yijoon Kim, Jin-Mi Oh, Jae-chun Go, DaeSik Kim, Chung-Gyu Park, Hyunsu Lee, Hyun Je Kim. "Immune cell-enriched single-cell RNA sequencing unveils the interplay between infiltrated CD8⁺ T resident memory cells and choroid plexus epithelial cells in Alzheimer's disease." Journal of Neuroimmunology. Download PDFCo-first author. Built the brain-to-single-cell path from whole-brain harvest through enzymatic digestion, Percoll enrichment and FACS to 10x; identified exhausted CD8⁺ tissue-resident memory T cells engaging choroid-plexus epithelium at the blood–CSF barrier.
  • 2025Seong-Jun Kang*, Jeong-Ryeol Gong*, Seon-Pil Jin, Jin-Mi Oh, Hyunjin Jin, Yuji Lee, Yewon Moon, Dongjun Kim, Hyo Jeong Nam, Hyun Seung Choi, Sanha Hwang, Yun Jung Huh, Kyung Yeon Han, Jihwan Moon, Jongsuk Chung, Woong-Yang Park, Chung-Gyu Park, Hyun Je Kim, Jeong Eun Kim. "Deciphering Dysfunctional Regulatory T Cells in Atopic Dermatitis." Allergy. Download PDF
  • 2024Jong-Min Kim*, Seong-Jun Kang*, So-Hee Hong*, Hyunwoo Chung, Jun-Seop Shin, Byoung-Hoon Min, Hyun Je Kim, Jongwon Ha, Chung-Gyu Park. "Long-term control of diabetes by tofacitinib-based immunosuppressive regimen after allo-islet transplantation in diabetic rhesus monkeys that rejected previously transplanted porcine islets." Xenotransplantation. Download PDFCo-first author. Long-term diabetes control with a tofacitinib-based regimen after allo-islet transplantation in rhesus macaques, with longitudinal immune monitoring.
  • 2022Youngkyoung Lim*, Seong-Jun Kang*, Beom Keun Cho, Hyun Je Kim, … Chong Hyun Won, Chung-Gyu Park. "Intra-tumoral heterogeneity and immune escape of melanoma arising from congenital melanocytic nevus revealed by spatial gene expression profiling." JEADV. Download PDF
  • 2019Jong-Min Kim*, Jun-Seop Shin*, Byoung-Hoon Min*, Seong-Jun Kang*, Il-Hee Yoon, Hyunwoo Chung, Jiyeon Kim, Eung-Soo Hwang, Jongwon Ha, Chung-Gyu Park. "JAK3 inhibitor-based immunosuppression in allogeneic islet transplantation in cynomolgus monkeys." Islets. Download PDFCo-first author, one of four authors contributing equally. JAK3-inhibitor-based immunosuppression in allogeneic islet transplantation in cynomolgus macaques.
Contributing Author
  • 2026Jung Ho Lee*, Sung Ha Lim*, Hyungdon Kook, Seong-Jun Kang, Geon Lee, Brian Hyohyoung Lee, Hyunsung Nam, YongJun Kim, Christine Suh-Yun Joh, Soyoung Jeong, Dongryeol Shin, Hyun Je Kim, Jiyoung Ahn. "Mycosis Fungoides-like Atopic Dermatitis Represents a Th22-dominant Inflammatory Endotype." Allergy.
  • 2024Brian Hyohyoung Lee*, Yoon Ji Bang*, Sung Ha Lim*, Seong-Jun Kang, Sung Hee Kim, Seunghee Kim-Schulze, Chung-Gyu Park, Hyun Je Kim, Tae-Gyun Kim. "High-dimensional profiling of regulatory T cells in psoriasis reveals an impaired skin-trafficking property." eBioMedicine. Download PDF
  • 2024Youngkyoung Lim*, Beom Keun Cho*, Seong-Jun Kang, Soyoung Jeong, Hyun Je Kim, Jiyoon Baek, Ji Hwan Moon, Cheol Lee, Chan-Sik Park, Je-Ho Mun, Chong Hyun Won, Chung-Gyu Park. "Spatial transcriptomic analysis of tumour–immune cell interactions in melanoma arising from congenital melanocytic nevus." JEADV. Download PDF
  • 2023Sunyoung Jung*, Sunho Lee, Hyun Je Kim, Sueon Kim, Ji Hwan Moon, Hyunwoo Chung, Seong-Jun Kang, Chung-Gyu Park. "Mesenchymal stem cell-derived extracellular vesicles subvert Th17 cells by destabilizing RORγt through posttranslational modification." Experimental & Molecular Medicine.
  • 2022Sangho Lee, Han-Teo Lee, Young Ah Kim, Il-Hwan Lee, Seong-Jun Kang, Kyeongpyo Sim, Chung-Gyu Park, Kyungho Choi, Hong-Duk Youn. "The optimized core peptide derived from CABIN1 efficiently inhibits calcineurin-mediated T-cell activation." Experimental & Molecular Medicine.
  • 2021So Hee Hong, Hyun Je Kim, Seong-Jun Kang, Chung-Gyu Park. "Novel Immunomodulatory Approaches for Porcine Islet Xenotransplantation." Current Diabetes Reports. Download PDF
  • 2020Sunho Lee, Sueon Kim, Hyunwoo Chung, Ji Hwan Moon, Seong-Jun Kang, Chung-Gyu Park. "Mesenchymal stem cell-derived exosomes suppress proliferation of T cells by inducing cell cycle arrest through p27kip1/Cdk2 signaling." Immunology Letters.
  • 2019Hyun Je Kim, Ji Hwan Moon, Hyunwoo Chung, Jun-Seop Shin, Bongi Kim, Jong Min Kim, Jung-Sik Kim, Il-Hee Yoon, Byoung-Hoon Min, Seong-Jun Kang, Yong-Hee Kim, Kyuri Jo, Joungmin Choi, Heejoon Chae, Won Woo Lee, Sun Kim, Chung-Gyu Park. "Bioinformatic analysis of peripheral blood RNA-sequencing sensitively detects the cause of late graft loss following overt hyperglycemia in pig-to-non-human primate islet xenotransplantation." Scientific Reports.
  • 2018Byoung-Hoon Min, Jun-Seop Shin, Jong-Min Kim, Seong-Jun Kang, Hyun-Je Kim, Il-Hee Yoon, Su-Kyoung Park, Ji-won Choi, Min-Suk Lee, Chung-Gyu Park. "Delayed revascularization of islets after transplantation by IL-6 blockade in pig-to-non-human primate islet xenotransplantation model." Xenotransplantation.
  • 2018Jun-Seop Shin, Jong-Min Kim, Byoung-Hoon Min, Il Hee Yoon, Hyun Je Kim, Jung-Sik Kim, Yong-Hee Kim, Seong-Jun Kang, Jiyeon Kim, Hee-Jung Kang, Dong-Gyun Lim, Eung-Soo Hwang, Jongwon Ha, Sang-Joon Kim, Wan Beom Park, Chung-Gyu Park. "Pre-clinical results in pig-to-non-human primate islet xenotransplantation using anti-CD40 antibody (2C10R4)-based immunosuppression." Xenotransplantation.
  • 2018Jong-Min Kim, Jun-Seop Shin, Byoung-Hoon Min, Il Hee Yoon, Seong-Jun Kang, Won-Young Jeong, Sang-Joon Kim, Chung-Gyu Park. "Pre-Clinical Results of Islet Allo-Transplantation Using JAK Inhibitor as Replacement for Tacrolimus in Cynomolgus Monkeys." Transplantation.
  • 2018Jung-Sik Kim, Hyunwoo Chung, Nari Byun, Seong-Jun Kang, Sunho Lee, Jun-Seop Shin, Chung-Gyu Park. "Construction of EMSC-islet co-localizing composites for xenogeneic porcine islet transplantation." Biochemical and Biophysical Research Communications.
Manuscripts in Preparation
  • 2026Kangsan Roh*, Sabyasachi Das*, Seong-Jun Kang, Olga Barreiro, Rodrigo Javier Gonzalez, Timothy P. Padera, Shraddha Shirguppe, Ahlim Lee, Youngju Song, Pazhanichamy Kalailingam, Claire E. Fong, Aarushi Gandhi, Meehyun Kim, Diana Tambala, Adam Vernon Crain, Casey A. Maguire, Ulrich H. Von Andrian, Christian L. Lino Cardenas, Sekeun Kim, Benjamin P. Kleinstiver, Mark E. Lindsay, Patricia L. Musolino, Rajeev Malhotra. "In-vivo base editing of ACTA2 R179H restores lymphatic function and immune cell homeostasis in a murine model of Multisystemic Smooth Muscle Dysfunction Syndrome (MSMDS)." in preparationCo-author (immunology). Ran the Olink plasma proteomics across 12 patients and 6 controls and the flow-cytometry immunophenotyping of lymph-node leukocytes.

Selected Grant Writing & Program Funding

Industry · PB Immune Therapeutics (Manager → Associate Director)
Funding Agency / SponsorProjectPeriodBudget (USD)Role / Contribution
Korea Drug Development Fund (KDDF)Anti-CD40 antibody lead selection and optimization (multiple sclerosis)2021–2023~$571,000Lead proposal writer (>90% of proposal & execution)
Korea Drug Development Fund (KDDF)Anti-CD40 lead compound (PB101): efficacy and pharmacodynamic biomarkers (pemphigus vulgaris)2022–2024~$321,000Lead proposal writer (>90% of proposal & execution)
Ministry of SMEs and Startups (MSS)Scale-up Funding for Tech Commercialization2022–2023~$222,000Lead proposal writer; managed >90% of execution
Ministry of SMEs and Startups (MSS)Early-stage startup R&D: anti-CD40 biologic (PB-40N) to prevent anti-drug antibodies2021–2022~$74,000Lead proposal writer & core researcher
NAVER CorporationEngineered regulatory T cells for immune-mediated diseases (PB20X_Treg)2023–2026~$128,000Proposal & study design (~50%)
Doctoral training · Seoul National University
Funding Agency / SponsorProjectPeriodBudget (USD)Role / Contribution
Ministry of Science and ICT (MSIT)Multi-layered immune-disease single-cell map for molecular target discovery (SCAID, A9-22-1-05)2022–2028 (3+3)~$1.6MParticipated in proposal writing (>30%)
Ministry of Education (MOE) & Ministry of Science and ICT (MSIT)Laboratory-Specialized Tech-Transfer & R&BD Grant2020–2021~$40,000Grant writing, experimental design & technical validation
All grants were held by the institutional Principal Investigator (Ph.D. advisor at SNU; company CEO/CSO at PB Immune Therapeutics); the listed roles reflect the applicant's contribution to proposal writing and project execution, not as PI. Budgets converted at ≈ ₩1,400 / USD.

Awards, Patents & Scholarships

Patents
2024
Antagonistic Anti-CD40 Humanized Antibody. Republic of Korea, Appl. No. 10-2024-0085972; registered 2024-07-01. Co-inventor.
2019
Immunosuppression Composition Comprising JAK Inhibitor. Republic of Korea, Appl. No. 10-2014-3490000; registered 2019-08-20.
Awards
2024
Grand Prize, 2024 GPTers AI Hackathon (Project GAIA Team)
2023
Grand Prize, SBA Smart Workathon (Work Process Innovation)
2017
Best Poster Award, American Transplant Congress, Chicago · Best Presentation Award, Korean Association of Immunologists
Scholarships
2014–2020
NRF Research Scholarship for Ph.D. Candidates · Dean's Lecture & Research Support Scholarship, SNU College of Medicine · BK21 Plus Research Scholarship

Selected Presentations

Poster
KAI Annual Meeting, Incheon (2022) · Cytokine, Hawaii (2022) · American Transplant Congress, Chicago (2017) · The Transplantation Society, Hong Kong (2016) · IPITA/IXA/CTS, Melbourne (2015) · TREG, Shanghai (2012)

References

Chung-Gyu Park, M.D., Ph.D.
Professor, Microbiology & Immunology / Biomedical Sciences, SNU College of Medicine; CEO/CSO, PB Immune Therapeutics · chgpark@snu.ac.kr
Doctoral advisor and industry supervisor; directed the anti-CD40 antibody program.
Hyun Je Kim, M.D., Ph.D.
Assistant Professor, Microbiology & Immunology / Biomedical Sciences; Interdisciplinary Program in Artificial Intelligence (IPAI), SNU · tte9801@snu.ac.kr
Co-corresponding on the single-cell studies; supervised the computational work.
Seung-Kuy Cha, Ph.D.
Professor, Dept. of Physiology & Global Medical Science, Yonsei University Wonju College of Medicine · skcha@yonsei.ac.kr
Most recent research supervisor (2025–2026).
Jeong Seok Lee, M.D., Ph.D.
Associate Professor, Graduate School of Medical Science & Engineering, KAIST, Daejeon · chemami@kaist.ac.kr
Corresponding author, PDE4D / Nature Immunology study.
Seong-Jun Kang · Curriculum Vitae · MIT Jameel ClinicAvailable from August 2026 · based in Boston, MA · currently authorized to work in the United States without employer sponsorship to begin employmentUpdated August 2026